ELTP
Elite Pharmaceuticals Inc /Nv/Company with tickers: ELTP
CIK
1053369
CUSIP
28659T200
Shares Outstanding
1,076,996,442
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $108,122,052 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Cost of Revenue | $53,869,874 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Gross Profit | $54,252,178 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Operating Expenses | $15,325,782 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Research & Development | $4,100,936 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Operating Income | $38,926,396 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| Net Income | $26,411,498 | USD | 2025-12-31 | 10-Q | 2026-02-17 |
| EPS (Basic) | $0.02 | USD/shares | 2025-12-31 | 10-Q | 2026-02-17 |
| EPS (Diluted) | $0.02 | USD/shares | 2025-12-31 | 10-Q | 2026-02-17 |